Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors

References

• US FDA . Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry (2018). www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf
   Google Scholar
• Roviello G , AndreF , VenturiniSet al. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies. Eur. J. Cancer86, 257–265 (2017).
   PubMed Web of Science ®Google Scholar
• Mushti S , MulkeyF , SridharaR. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clin. Cancer Res.24, 2268–2275 (2018).
   PubMed Web of Science ®Google Scholar
• Larkin J , Chiarion-SileniV , GonzalezRet al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med.381, 1535–1546 (2019).
   PubMed Web of Science ®Google Scholar
• Robert C , SchachterJ , LongGVet al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med.372, 2521–2532 (2015).
   PubMed Web of Science ®Google Scholar
• Robert C , LongGV , BradyBet al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med.372, 320–330 (2015).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodriguez-AbreuD , RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive-non-small-cell lung cancer. N. Engl. J. Med.375, 1823–1833 (2016).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L , LuftA , VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379, 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• Gandhi L , Rodriguez-AbreuD , GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med.378, 2078–2092 (2018).
   PubMed Web of Science ®Google Scholar
• Albiges L , TannirNM , BurottoMet al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open5(6), e001079 (2020).
   PubMed Web of Science ®Google Scholar
• Powles T , PlimackER , SoulieresDet al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomized, open-label, phase 3 trial. Lancet Oncol.21, 1563–1573 (2020).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , MotzerRJ , RiniBIet al. Updated efficacy from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol.31, 1030–1039 (2020).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , PowlesT , BurottoMet al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. N. Engl. J. Med.384, 829–841 (2021).
   PubMed Web of Science ®Google Scholar
• Motzer R , AlekseevB , RhaSYet al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med.384, 1289–1300 (2021).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP , BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45, 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Petrelli F , BorgonovoK , CabidduM , GhilardiM , LonatiV , BarniS. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J. Gastrointest. Oncol.8, 39–48 (2017).
   PubMed Web of Science ®Google Scholar
• Ozkurt E , SakaiT , WongSM , TukenmezM , GolshanM. Survival outcomes for patients with clinical complete response after neoadjuvant chemotherapy: is omitting surgery an option?Ann. Surg. Oncol.26, 3260–3268 (2019).
   PubMedGoogle Scholar
• Huang M , O’ShaughnessyJ , ZhaoJet al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res.80(24), 5427–5434 (2020).
   PubMed Web of Science ®Google Scholar
• Hamid O , RobertC , DaudAet al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol.30, 582–588 (2019).
   PubMed Web of Science ®Google Scholar
• Voss MH , MotzerRJ , AlbigesLet al. Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. Oncol. Res. Treat.43(Suppl. 1), 225 (2020).
   Google Scholar
• Warner AB , PalmerJS , ShoushtariANet al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J. Clin. Oncol.38. 1655–1665 (2020).
   PubMedGoogle Scholar
• Gauci ML , LanoyE , ChampiatSet al. A long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin. Cancer Res.25, 946–956 (2019).
   PubMed Web of Science ®Google Scholar
• Tannock IF , AmirE , BoothCMet al. Relevance of randomised controlled trials in oncology. Lancet Oncol.17, e560–e567 (2016).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB , McDermottDFet al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow up of a randomized phase 3 clinical trial. J. Immunother. Cancer8, e000891 (2020).
   PubMed Web of Science ®Google Scholar
• Robert C , RibasA , HamidOet al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol.36, 1668–1674 (2018).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . Duration of anti-PD-1 therapy in metatatic melanoma (STOP-GAP) (2022). https://clinicaltrials.gov/ct2/show/NCT02821013?recrs=a&cond=melanoma&cntry=CA&city=kingston&draw=2&rank=2
   Google Scholar